High-Flow Nasal Oxygen versus Noninvasive Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Randomized Controlled Trials.

IF 2.1 4区 医学 Q3 RESPIRATORY SYSTEM Canadian respiratory journal Pub Date : 2023-01-01 DOI:10.1155/2023/7707010
Yanping Du, Huaping Zhang, Zhiyi Ma, Jun Liu, Zhiyong Wang, Meixia Lin, Fayu Ni, Xi Li, Hui Tan, Shifan Tan, Yanling Chai, Xiangzhu Zhong
{"title":"High-Flow Nasal Oxygen versus Noninvasive Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Randomized Controlled Trials.","authors":"Yanping Du,&nbsp;Huaping Zhang,&nbsp;Zhiyi Ma,&nbsp;Jun Liu,&nbsp;Zhiyong Wang,&nbsp;Meixia Lin,&nbsp;Fayu Ni,&nbsp;Xi Li,&nbsp;Hui Tan,&nbsp;Shifan Tan,&nbsp;Yanling Chai,&nbsp;Xiangzhu Zhong","doi":"10.1155/2023/7707010","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>High-flow nasal cannula (HFNC) can be used in stable chronic obstructive pulmonary disease (COPD) patients, but the effect of HFNC on clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is still uncertain.</p><p><strong>Methods: </strong>We searched electronic literature databases for randomized controlled trials (RCTs) comparing HFNC with noninvasive ventilation (NIV) in hypercapnic patients with AECOPD. The primary endpoint of this meta-analysis was PaCO<sub>2</sub>, PaO<sub>2,</sub> and SpO<sub>2</sub>. The secondary outcomes were the respiratory rate, mortality, complications, and intubation rate.</p><p><strong>Results: </strong>We included 7 RCTs with a total of 481 patients. There were no significant differences on measures of PaCO<sub>2</sub> (MD = -0.42, 95%CI -3.60 to 2.75, <i>Z</i> = 0.26, and <i>P</i> = 0.79), PaO<sub>2</sub> (MD = -1.36, 95%CI -4.69 to 1.97, <i>Z</i> = 0.80, and <i>P</i> = 0.42), and SpO<sub>2</sub> (MD = -0.78, 95%CI -1.67 to 0.11, <i>Z</i> = 1.72, <i>P</i> = 0.08) between the HFNC group and the NIV group. There was no significant difference in measures of the mortality and intubation rate between the HFNC group (OR = 0.72, 95%CI 0.30 to 1.69, <i>Z</i> = 0.76, and <i>P</i> = 0.44) and the NIV group (OR = 2.38, 95%CI 0.49 to 11.50, <i>Z</i> = 1.08, and <i>P</i> = 0.28), respectively. But the respiratory rate in the HFNC group was lower than that in the NIV group (MD = -1.13, 95%CI -2.13 to -0.14, <i>Z</i> = 2.23, and <i>P</i> = 0.03), and fewer complications were found in the HFNC group (OR = 0.26, 95%CI 0.14 to 0.47, <i>Z</i> = 4.46, and <i>P</i> < 0.00001).</p><p><strong>Conclusion: </strong>NIV was noninferior to HFNC in decreasing PaCO<sub>2</sub> and increasing PaO<sub>2</sub> and SpO<sub>2</sub>. Similarly, the mortality and intubation rate was similar among the two groups. The respiratory rate and complications were inferior in the AECOPD group treated with HFNC.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2023 ","pages":"7707010"},"PeriodicalIF":2.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328729/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian respiratory journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/7707010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 1

Abstract

Background: High-flow nasal cannula (HFNC) can be used in stable chronic obstructive pulmonary disease (COPD) patients, but the effect of HFNC on clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is still uncertain.

Methods: We searched electronic literature databases for randomized controlled trials (RCTs) comparing HFNC with noninvasive ventilation (NIV) in hypercapnic patients with AECOPD. The primary endpoint of this meta-analysis was PaCO2, PaO2, and SpO2. The secondary outcomes were the respiratory rate, mortality, complications, and intubation rate.

Results: We included 7 RCTs with a total of 481 patients. There were no significant differences on measures of PaCO2 (MD = -0.42, 95%CI -3.60 to 2.75, Z = 0.26, and P = 0.79), PaO2 (MD = -1.36, 95%CI -4.69 to 1.97, Z = 0.80, and P = 0.42), and SpO2 (MD = -0.78, 95%CI -1.67 to 0.11, Z = 1.72, P = 0.08) between the HFNC group and the NIV group. There was no significant difference in measures of the mortality and intubation rate between the HFNC group (OR = 0.72, 95%CI 0.30 to 1.69, Z = 0.76, and P = 0.44) and the NIV group (OR = 2.38, 95%CI 0.49 to 11.50, Z = 1.08, and P = 0.28), respectively. But the respiratory rate in the HFNC group was lower than that in the NIV group (MD = -1.13, 95%CI -2.13 to -0.14, Z = 2.23, and P = 0.03), and fewer complications were found in the HFNC group (OR = 0.26, 95%CI 0.14 to 0.47, Z = 4.46, and P < 0.00001).

Conclusion: NIV was noninferior to HFNC in decreasing PaCO2 and increasing PaO2 and SpO2. Similarly, the mortality and intubation rate was similar among the two groups. The respiratory rate and complications were inferior in the AECOPD group treated with HFNC.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性阻塞性肺疾病急性加重期患者的高流量鼻吸氧与无创通气:随机对照试验的荟萃分析
背景:高流量鼻插管(HFNC)可用于稳定期慢性阻塞性肺疾病(COPD)患者,但HFNC对慢性阻塞性肺疾病急性加重期(AECOPD)患者临床结局的影响尚不明确。方法:我们检索电子文献数据库,比较HFNC与无创通气(NIV)治疗AECOPD高碳酸血症患者的随机对照试验(rct)。这项荟萃分析的主要终点是PaCO2、PaO2和SpO2。次要结局为呼吸频率、死亡率、并发症和插管率。结果:我们纳入了7项随机对照试验,共481例患者。HFNC组与NIV组PaCO2 (MD = -0.42, 95%CI -3.60 ~ 2.75, Z = 0.26, P = 0.79)、PaO2 (MD = -1.36, 95%CI -4.69 ~ 1.97, Z = 0.80, P = 0.42)、SpO2 (MD = -0.78, 95%CI -1.67 ~ 0.11, Z = 1.72, P = 0.08)指标无显著差异。HFNC组(OR = 0.72, 95%CI 0.30 ~ 1.69, Z = 0.76, P = 0.44)与NIV组(OR = 2.38, 95%CI 0.49 ~ 11.50, Z = 1.08, P = 0.28)的死亡率和插管率指标无显著差异。但HFNC组呼吸频率低于NIV组(MD = -1.13, 95%CI为-2.13 ~ -0.14,Z = 2.23, P = 0.03),并发症发生率低于NIV组(OR = 0.26, 95%CI为0.14 ~ 0.47,Z = 4.46, P)。结论:NIV在降低PaCO2、升高PaO2和SpO2方面不低于HFNC组。同样,两组的死亡率和插管率相似。HFNC治疗AECOPD组呼吸频率及并发症均较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Canadian respiratory journal
Canadian respiratory journal 医学-呼吸系统
CiteScore
4.20
自引率
0.00%
发文量
61
审稿时长
6-12 weeks
期刊介绍: Canadian Respiratory Journal is a peer-reviewed, Open Access journal that aims to provide a multidisciplinary forum for research in all areas of respiratory medicine. The journal publishes original research articles, review articles, and clinical studies related to asthma, allergy, COPD, non-invasive ventilation, therapeutic intervention, lung cancer, airway and lung infections, as well as any other respiratory diseases.
期刊最新文献
Associations of Vitamin D With GPX4 and Iron Parameters in Chronic Obstructive Pulmonary Disease Patients: A Case-Control Study. Geographic Differences in Availability and Access to Care Services for Asthma and COPD: Case Study of Vancouver Coastal Health, British Columbia. Clinical Analysis of 32 Cases of Subglottic Benign Airway Stenosis Treated With Montgomery T Silicone Stent. Nomograms for Predicting High Hospitalization Costs and Prolonged Stay among Hospitalized Patients with pAECOPD. Gentiopicroside Ameliorates Sepsis-Induced Acute Lung Injury via Inhibiting Inflammatory Response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1